Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Regeneron Pharmaceuticals
Linnaeus Therapeutics, Inc.
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
University of California, Irvine
M.D. Anderson Cancer Center
Incyte Corporation
Novartis
Massachusetts General Hospital
Bayer
SRH Wald-Klinikum Gera GmbH
NYU Langone Health
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Novartis
Boehringer Ingelheim
Iovance Biotherapeutics, Inc.
Seagen Inc.
National Institutes of Health Clinical Center (CC)
Compass Therapeutics
Pliant Therapeutics, Inc.
Nested Therapeutics, Inc
Iovance Biotherapeutics, Inc.
M.D. Anderson Cancer Center
Compass Therapeutics
Novartis
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Hangzhou Hanx Biopharmaceuticals, Ltd.
University of Pittsburgh
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
M.D. Anderson Cancer Center
Genentech, Inc.
Nantes University Hospital
Boehringer Ingelheim
Shanghai Henlius Biotech
The Netherlands Cancer Institute
Herlev and Gentofte Hospital
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Canadian Cancer Trials Group
Institut Claudius Regaud
Diakonos Oncology Corporation